期刊
FRONTIERS IN GENETICS
卷 14, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2023.1184600
关键词
ERBB2 (HER2/neu); 3'UTR elements; cancer; drug resistance; cancer treatment; mRNA stabilizing; mRNA overwriting
Resistance to targeted therapy is a challenge in breast, lung, and colorectal cancers, leading to a large number of deaths annually. We found that ERBB2+ cancer cells have mRNA-stabilizing sequences on their 3'UTR. By manipulating these sequences, we successfully degraded ERBB2 transcripts and reduced protein levels in various cancer cell types, providing a new approach to control oncogenic signals where current therapies fail.
Breast, lung, and colorectal cancer resistance to molecular targeted therapy is a major challenge that unfavorably impacts clinical outcomes leading to hundreds of thousands of deaths annually. In ERBB2+ cancers regardless of the tissue of origin, many ERBB2+ cancers are resistant to ERBB2-targeted therapy. We discovered that ERBB2+ cancer cells are enriched with poly U sequences on their 3'UTR which are mRNA-stabilizing sequences. We developed a novel technology, in which we engineered these ERBB2 mRNA-stabilizing sequences to unstable forms that successfully overwrote and outcompeted the endogenous ERBB2 mRNA-encoded message and degraded ERBB2 transcripts which led to the loss of the protein across multiple cancer cell types both in the wildtype and drug-resistance settings in vitro and in vivo, offering a unique safe novel modality to control ERBB2 mRNA and other pervasive oncogenic signals where current targeted therapies fail.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据